Global Gadopentetate Dimeglumine Market Overview:
The contrast agent gadopentetate dimeglumine has magnetic properties. It is used in conjunction with magnetic resonance imaging (MRI) to enhance the visibility of blood vessels, lungs, and other non-bony tissues on the MRI. Gadopentetate dimeglumine is used to diagnose some brain, blood vessel, and spin disorders (central nervous system). It's used to help with imaging of blood vessels, as well as inflamed or diseased tissue where blood vessels have been "leaky." It is often used for viewing intracranial lesions with irregular vascularity or anomalies in the blood–brain barrierIt's typically given as an intravenous injection. The gadolinium contrast medium Gd-DTPA is classified as an acyclic, ionic gadolinium contrast medium. Its paramagnetic property decreases the T1 relaxation time (and to a lesser degree the T2 and T2* relaxation times) in NMR, which is why it's useful in medicine. Increased incidences of chronic diseases, the demand for image-guided procedures and diagnostics, and a large number of contrast agent approvals are all driving the growth of the contrast media industry. The use of image-guided procedures will aid in determining whether a cancer is malignant or benign. With the rising prevalence and number of cancer cases in both emerging and developed economies around the world, protocols that can assist patients in receiving a diagnosis at an earlier stage are required. Some of the players profiled in the study are Bayer Ag (Germany), Bracco Diagnostic Inc. (Italy), GE Healthcare (United States), Guerbet Group (France), Spago Nanomedical AB (Sweden), Takeda Pharmaceutical, Fuji Pharma (Japan), BeiLu Pharma (China), J.B. Chemicals and Pharmaceuticals (India) and Lantheus Medical Imaging Inc. (United States).
On the basis of geography, the market of Gadopentetate Dimeglumine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-User, the sub-segment i.e. Hospitals will boost the Gadopentetate Dimeglumine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Dosage, the sub-segment i.e. 10ml: 4.69g will boost the Gadopentetate Dimeglumine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Growth Drivers
- Increasing Prevalence of Cancer and other Diseases that Require Medical Imaging
- Technological Advancements in Imaging Solutions
- Increasing Demand for Early Diagnosis and Rise of MRI Examinations
- Several Side Effects Including Joint pains, Skin Discoloration, Headache etc.
- Increased Investment in R&D
- High cost of Injectors, Consumables, and Accessories
- Need of Various Regulatory Approvals
Key Market Developments:
December 2018 – Bracco Diagnostics Inc. Receives U.S. Food And Drug Administration (FDA) Approval for Use of Multihance (GadobenateDimeglumine) Injection, 529 Mg/Ml in Magnetic Resonance Imaging (MRI) of the Central Nervous System (CNS) in Pediatric Patients Younger Than 2 Years
Manufacturers of Gadopentetate Dimeglumine, Suppliers of Gadopentetate Dimeglumine, Wholesalers, Distributors and Retailers ofGadopentetate Dimeglumine, Pharmaceutical Companies, Medical Research Institutes and Governmental Bodies
Major Objectives Focused through this Study
To define, describe, and forecast the Global Gadopentetate Dimeglumine market on the basis of product  , application , key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the Gadopentetate Dimeglumine market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the Gadopentetate Dimeglumine industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Available Customization: Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Towaseiyaku Pharmaceutical (Japan), Hikari Pharmaceutical (Japan) and Sanochemia (Austria).
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the Gadopentetate Dimeglumine market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.